Phillips-Medisize announces the expansion to its Kontiolahti, Finland site.
Phillips-Medisize, an outsource provider of design and manufacturing services for medical devices and drug delivery markets, reports the start of production and completion of the 60,000-ft2expansion to its Kontiolahti, Finland site. Production has already begun and will continue to ramp up several new programs before the first of the year. The site focuses on the industrialization and production of inhalers, insulin pens, transfer devices, and syringes.
The expansion includes 12,900 ft2 of Class 8 clean-room manufacturing and assembly and has space for the additional expansion for molding machines and assembly. New high-speed automation lines enable the ramp up of multi-component, complex drug-delivery devices from prototype to high-speed automated 24/7 mass production under competitive cost-structure. Total Kontiolahti numbers now include, multiple high-speed, fully automated assembly lines, fully automated printing lines, and several semi-automated lines.
Source: Phillips-Medisize
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.